Chemotherapy-Induced Acral Erythema: A Clinical and Histopathologic Study of 44 Cases

Hueso, L.; Sanmartín, O.; Nagore, Eduardo; Botella‐Estrada, Rafael; Requena, Celia; Llombart, B.; Serra‐Guillén, C.; Alfaro‐Rubio, A.; Guillén, C.

doi:10.1016/s1578-2190(08)70252-x

Cited by 30 publications

(41 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in contrast to our patient who developed her symptoms after the 6th weekly dose (80 mg/m 2 ) of paclitaxel. Paclitaxel-induced HFS could be dependent on cumulative doses of the drug, as reported with other chemotherapeutic agents [5,7]. …”

Section: Discussionmentioning

confidence: 77%

“…Of the 127 patients who received paclitaxel, only 2 patients developed grade 2 HFS [7]. This corresponds to an occurrence rate of 1.5%.…”

Section: Discussionmentioning

confidence: 99%

“…Like many other antineoplastic drugs, they have various toxicities that include myelosupression, neuropathies, and mucocutaneous manifestations [2]. Although docetaxel, a widely used taxane chemotherapeutic agent, has been linked to palmoplantar dysesthesia in clinical trials, clinical practice, and many case reports [3,4,5], such an association has not been as frequently established with paclitaxel, except in 3 reported cases and in 1 prospective study [2,3,6,7]. When HFS is diagnosed, physicians usually discontinue the offending agent, and the syndrome starts to resolve slowly, with residual skin pigmentation in some cases [2,8,9,10,11].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Management of Paclitaxel-Induced Hand-Foot Syndrome

et al. 2013

View full text Add to dashboard Cite

Background: Hand-foot syndrome (HFS), also known as acral erythema or palmoplantar dysesthesia, is a manifestation of painful erythema and dysesthesia mostly occurring in the palms and soles. Although many chemotherapeutic agents have been shown to cause HFS, it remains an uncommon adverse cutaneous manifestation of paclitaxel. Case Report: We report a case of paclitaxel-induced grade 3 HFS in a patient with breast cancer. HFS developed after 6 weeks of paclitaxel weekly infusions. The patient was managed by avoidance of sun exposure and extensive use of sunscreen and moisturizers. The skin lesions stabilized and improved gradually. This allowed us to continue the planned necessary course of 12 weeks of paclitaxel under close surveillance. Conclusion: Paclitaxel-induced HFS can be managed with topical creams and avoidance of sun exposure without the need to discontinue chemotherapy. However, close monitoring for any increase or change in symptoms is warranted.

show abstract

Section: Discussionmentioning

confidence: 77%

“…Of the 127 patients who received paclitaxel, only 2 patients developed grade 2 HFS [7]. This corresponds to an occurrence rate of 1.5%.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Management of Paclitaxel-Induced Hand-Foot Syndrome

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Other common effects are nausea and vomiting, hair loss (alopecia), and hand-foot syndrome (clinically characterized by painful, symmetrical erythema of the palms and soles, often preceded by paresthesias in the affected zones) (3,4). Most of the side effects gradually disappear after the end of treatment, though in some cases permanent damage may be observed at cardiac (myocardiopathy), pulmonary (fibrosis), renal (chronic renal failure) or reproductive level (sterility).…”

Section: General Side Effects Of Chemotherapymentioning

confidence: 99%

Dental treatment considerations in the chemotherapy patient

López¹,

Esteve²,

Pérez³

2011

J Clin Exp Dent

View full text Add to dashboard Cite

Cancer patients can suffer oral toxic effects secondary to antineoplastic therapy in the form of radiotherapy and/ or chemotherapy. This risk is conditioned by a range of factors, including the high cell turnover rate of the oral mucosa, the diversity and complexity of the oral microflora, and soft tissue trauma during normal oral function. The present study offers a literature review of the main oral complications secondary to chemotherapy, and describes the different options for dental treatment before, during and after oncological treatment, published in the scientific literature. To this effect a PubMed-Medline® search was made using the following keywords: chemotherapy, cancer therapy, dental management, oral mucositis, neurotoxicity, intravenous bisphosphonates and jaw osteonecrosis. The search was limited to human studies published in the last 10 years in English or Spanish. A total of 50 articles were identified: 17 research papers, 25 reviews, 6 letters to the Editor, and two clinical guides developed by expert committees. The data obtained showed the main oral complications of chemotherapy to be mucositis, neurotoxicity, susceptibility to infections, dental, salivary and taste alterations, and the development of osteonecrosis. Based on the reviewed literature, elective dental treatment can be provided before chemotherapy, with emphasis on the elimination of infectious foci. During chemotherapy, dental treatment should be limited to emergency procedures, while dental treatment of any kind can be prescribed after chemotherapy -with special considerations in the case of patients who have received treatment with intravenous bisphosphonates.

show abstract

“…Symptoms may begin anywhere from weeks to years after initiation of hydroxyurea [2,3]. The histopathology of acral erythema typically demonstrates an interface dermatitis at the dermal-epidermal junction with a sparse inflammatory infiltrate [4]. The reaction is variably reversible with discontinuation of the medication but symptoms of pain and discomfort can persist for months.…”

mentioning

confidence: 99%

Hydroxyurea‐associated acral erythema in a patient with polycythemia vera

2014

View full text Add to dashboard Cite

A 64-year old man presented with 3 years of progressive redness, burning, and peeling of his palms and soles. His past medical history included cutaneous squamous cell carcinoma, malignant melanoma, gout, and polycythemia vera which had been diagnosed 10 years earlier and complicated by a significant gastrointestinal bleed. Genetic analysis demonstrated a mutant JAK-2 V617F allele. He had been treated with therapeutic phlebotomies and with hydroxyurea 1 g daily, with dose escalation to 1.5 g daily over the last 3 years for management of his polycythemia and worsening splenomegaly.On examination, he had desquamating erythema of the palms and soles, extending proximally to the flexures of the wrists and heels (Images 1A, 1B, 1C). The patient reported that his symptom worsened as the dose of hydroxyurea was increased over the previous 3 years. A diagnosis of hydroxyurea-associated acral erythema was made. The dorsal hands also demonstrate pink-red erythema with accentuation over the interphalangeal and metacarpophalangeal joints. (C) The bilateral soles also reveal consistent pink-red erythema with accentutation in areas of weightbearing and additional areas of hyperkeratosis and focal desquamation.

show abstract

Chemotherapy-Induced Acral Erythema: A Clinical and Histopathologic Study of 44 Cases

Cited by 30 publications

References 54 publications

Management of Paclitaxel-Induced Hand-Foot Syndrome

Management of Paclitaxel-Induced Hand-Foot Syndrome

Dental treatment considerations in the chemotherapy patient

Hydroxyurea‐associated acral erythema in a patient with polycythemia vera

Contact Info

Product

Resources

About